Oxford Biomedica eyes ABL Europe acquisition to bolster cell and gene therapy CDMO operations
Oxford Biomedica plc and Institut Mérieux SA have entered exclusive negotiations concerning Oxford Biomedica's proposed acquisition of ABL Europe SAS. This acquisition, valued at €15 ... Read More